Comunicati Stampa
Salute e Benessere

Telix Spins Off Rhine Pharma™ to Expand Global Access to Radiopharmaceuticals

Because 99mTc and 188Re can each be produced using on-site generators, they enable a highly-differentiated solution for regions with limited radiopharmaceutical manufacturing infrastructure or dispersed populations. 99mTc enables imaging of patients with widely available SPECT scanners, while 188Re has demonstrated potential as a therapeutic isotope, thanks to its high-energy beta emission that maximises damage to tumour cells. Its short half-life (16.9 hours) also has the potential to simplify patient workflows in busy treatment centres with high patient demand or limited nuclear waste management capabilities.
MELBOURNE, Australia, (informazione.it - comunicati stampa - salute e benessere)

Because Tc and Re can each be produced using on-site generators, they enable a highly-differentiated solution for regions with limited radiopharmaceutical manufacturing infrastructure or dispersed populations. Tc enables imaging of patients with widely available SPECT scanners, while Re has demonstrated potential as a therapeutic isotope, thanks to its high-energy beta emission that maximises damage to tumour cells. Its short half-life (16.9 hours) also has the potential to simplify patient workflows in busy treatment centres with high patient demand or limited nuclear waste management capabilities.

Radiopharmaceuticals based on more common therapeutic radioisotopes (on market or in development) such as lutetium-177 ( Lu) and actinium-225 ( Ac), are typically centrally manufactured in facilities that require significant investment and infrastructure to operate, such as reactors or cyclotrons. By contrast, a generator is a convenient system for on-site production of some commonly-used radionuclides.

Richard Valeix, Chief Executive Officer, Therapeutics, Telix, said, "Rhine Pharma is an example of identifying an access-to-medicine challenge and then working to fix it. While radiopharmaceuticals can be a powerful way to image and treat cancer, manufacturing doses and getting them to patients can be complex and costly, particularly in emerging markets or geographically dispersed populations. Using generators for production could reduce costs and simplify the supply chain. This means the combination of Re and Tc has potential for addressing unmet needs in cancer treatment for more people, in more countries."

Christian Behrenbruch , Managing Director and Group Chief Executive Officer, Telix, said, "This is an exciting story of collaborative innovation aligned with our values, particularly our commitment to increasing access to medicine. It also demonstrates Telix's ability to drive in-house innovation that can move seamlessly from the laboratory to the clinic and evolve commercially. Spinning off Rhine Pharma makes room in our pipeline for future opportunities and gives Rhine Pharma the focus it needs to succeed."

Rhine Pharma is strongly supported by its renowned Founding Scientific Advisors - Professor Frederik Giesel , Professor Ken Herrmann , Professor Clemens Kratochwil and Dr Jens Cardinale - and is working closely with the Nuclear Medicine Research Infrastructure (NuMeRI), a groundbreaking facility at the University of Pretoria, South Africa . Opened in May 2024 , the facility is committed to advancing nuclear medicine research in the region. The RHINO Trial has received both ethics and regulatory approval in South Africa and is being run by NuMeRI's CEO and President, Professor Mike Sathekge , and his team.

Professor Sathekge said, "NuMeRI is working to bring the benefits of precision medicine and radiopharmaceutical therapy to more people, regardless of their location or income. It's only through innovation and collaboration that we can marshal the resources needed to achieve this goal, and partnering with Rhine Pharma on this clinical trial is an exciting opportunity to advance research in this area. We look forward to seeing how RHN001 performs in the clinic."

Rhine Pharma™ is a wholly-owned subsidiary of Telix and once key milestones are achieved, Telix plans to structure it as an independent company. Its mission is to expand global access to innovative cancer imaging and therapy by leveraging the unique benefits of technetium-99m ( Tc) and rhenium-188 ( Re).  Visit www.rhine-pharma.com for further information.

Telix is a biopharmaceutical company focused on the development and commercialisation of therapeutic and diagnostic radiopharmaceuticals and associated medical devices. Telix is headquartered in Melbourne, Australia , with international operations in the United States , Europe ( Belgium and Switzerland ), and Japan . Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX).

Telix's lead imaging product, gallium-68 ( Ga) gozetotide injection (also known as Ga PSMA-11 and marketed under the brand name Illuccix ), has been approved by the U.S. Food and Drug Administration (FDA) , by the Australian Therapeutic Goods Administration (TGA)  , and by Health Canada . No other Telix product has received a marketing authorisation in any jurisdiction.

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, announcements made to the ASX, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on X  and  LinkedIn .

Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com

Legal Notices

 


View original content: https://www.prnewswire.co.uk/news-releases/telix-spins-off-rhine-pharma-to-expand-global-access-to-radiopharmaceuticals-302283011.html

Ufficio Stampa
 PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom
Allegati
Non disponibili